Welcome to our dedicated page for Cingulate SEC filings (Ticker: CING), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cingulate Inc. (CING) SEC filings page on Stock Titan provides organized access to the company’s public disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Capital Market–listed biopharmaceutical company, Cingulate uses its SEC reports to describe progress of its Precision Timed Release™ (PTR™) platform, regulatory milestones for its lead ADHD candidate CTx-1301, and key financing and governance events.
Here you can review Form 8-K current reports that detail material events such as FDA acceptance of the New Drug Application for CTx-1301 with a May 31, 2026 PDUFA target action date, commercial supply agreements with Bend Bio Sciences, purchase agreements with Lincoln Park Capital, and promissory note financings with Avondale Capital. 8-K filings also summarize quarterly earnings press releases, special stockholder meeting results, and executive or board-level changes.
When available, annual reports on Form 10-K and quarterly reports on Form 10-Q provide broader discussion of Cingulate’s business, PTR technology, risk factors, and financial statements. These filings are particularly relevant for understanding the company’s clinical-stage status, R&D spending on CTx-1301 and other candidates in anxiety and neuropsychiatric indications, and its capital structure.
Investors interested in ownership and compensation matters can also monitor proxy statements and, where applicable, Form 4 insider transaction reports to see how directors and officers transact in CING securities. Stock Titan’s platform enhances these documents with AI-powered summaries that explain complex sections, highlight key terms in financing agreements, and surface important dates such as NDA submissions and PDUFA deadlines. Real-time updates from EDGAR ensure that new Cingulate filings, from 8-Ks to periodic reports, appear promptly with plain-language explanations to support deeper analysis of CING’s regulatory and financial disclosures.
Cingulate Inc. registers for resale up to 3,500,000 additional shares of common stock to be offered by Lincoln Park Capital Fund, LLC under a purchase agreement providing up to $25.0 million of committed equity financing.
The registration covers shares the company may elect to issue and sell to Lincoln Park under a July 21, 2025 Purchase Agreement; the company will control timing and may receive proceeds only if it sells Purchase Shares to Lincoln Park. Shares outstanding were 11,594,679 as of March 13, 2026; the prospectus shows an illustrative post-issuance count of 15,094,679 assuming sale of all 3,500,000 additional shares.
Falcon Creek Capital Advisor LLC and related funds filed an amended beneficial ownership report on Cingulate Inc. common stock after acquiring shares on 03/24/2026 under a Purchase Agreement. Falcon Creek Capital Advisor reports beneficial ownership of 3,856,766 shares, representing 28.50% of Cingulate’s common stock, with shared voting and dispositive power over all such shares. Falcon Creek Technology Fund I holds 350,195 shares, or 2.59%, and Ginkgo Capital Global Fund SPC – Xtalpi AI Fund holds 3,506,571 shares, or 25.91%, each with shared voting and dispositive power. The reporting persons describe their holdings as venture and investment positions and state that, aside from the Purchase Agreement and related arrangements, they have no other contracts or understandings concerning Cingulate’s securities.
Cingulate Inc. entered into an at-the-market equity sales agreement with A.G.P./Alliance Global Partners, allowing the company to sell common stock over time for aggregate gross proceeds of up to $100,000,000. A.G.P. will act as sales agent for these Nasdaq Capital Market transactions and receive a 3.0% commission on any shares sold.
Separately, stockholders at a special meeting approved issuing common stock upon conversion of Series A Convertible Preferred Stock and/or exercise of warrants under a January 27, 2026 securities purchase agreement, satisfying Nasdaq Listing Rule 5635(b) requirements. A related proposal to permit adjournment was also approved but ultimately not used.
Cingulate Inc. is registering common stock with an aggregate offering price of $100,000,000 for sale at-the-market through A.G.P./Alliance Global Partners pursuant to an At The Market Sales Agreement dated March 24, 2026.
The prospectus supplement states sales may be made on Nasdaq or other U.S. trading markets, A.G.P. will act as sales agent (entitled to a 3.0% commission) and the company intends to use net proceeds to advance CTx-1301 regulatory, development, manufacturing and commercialization activities and for general corporate purposes.
Cingulate Inc. filed Pre-Effective Amendment No. 1 to its registration statement to add an updated consent of KPMG LLP. The amendment does not modify the prospectus and leaves the registration statement's effective date delayed until the company files a further amendment specifying effectiveness in accordance with Section 8(a) of the Securities Act.
Cingulate Inc. files a prospectus to register up to 3,500,000 shares of common stock that it may elect to issue and sell to Lincoln Park Capital Fund, LLC under a purchase agreement, for resale by Lincoln Park. The prospectus also reflects registration of 6,000,000 shares in total, which includes previously registered and issued shares.
The Purchase Agreement permits Cingulate to sell up to $25.0 million of common stock to Lincoln Park over a 36-month term, subject to a Beneficial Ownership Cap of 4.99% (increaseable to 9.99% with notice). The company will control timing and amount of any sales to Lincoln Park and will receive proceeds only for shares it elects to sell to Lincoln Park under the Purchase Agreement.
Cingulate Inc. is a biopharmaceutical company developing next‑generation, once‑daily treatments using its Precision Timed Release (PTR) platform. Its lead ADHD candidate, CTx‑1301, has an NDA under FDA review with a PDUFA target action date of May 31, 2026.
CTx‑1301 aims to provide rapid onset within 30 minutes and full active‑day coverage, potentially avoiding afternoon booster doses. The company is also advancing ADHD candidate CTx‑1302 and anxiety candidate CTx‑2103, both built on the same PTR technology, and holds patents expected to provide protection into the 2030s and early 2040s.
Cingulate Inc. reported a larger full-year 2025 net loss of $22.4 million, up from $16.6 million, as general and administrative costs rose with pre-commercialization spending. Research and development expenses were $9.8 million, slightly above 2024, reflecting regulatory and manufacturing work on lead ADHD candidate CTx-1301.
Cash and cash equivalents were $11.0 million as of December 31, 2025, and the company expects its cash to fund operations into late fourth quarter of 2026 under its current plan. In February 2026, Cingulate closed a $12 million at-the-market PIPE financing with a 180‑day investor lock-up and board designation rights for Falcon Creek Capital.
Strategically, Cingulate advanced CTx-1301 with U.S. and European patent protection expected through May 2042 and FDA acceptance of its NDA, including a PDUFA target action date of May 31, 2026. A recent U.S. Notice of Allowance and granted European patent strengthen the intellectual property estate as the company prepares commercial manufacturing, market access, and distribution ahead of a potential launch.
Cingulate Inc. executive Raul R. Silva, EVP and CSO, received a grant of 4,526 shares of common stock on March 9, 2026 as part of his 2025 bonus under the company’s 2021 Omnibus Equity Incentive Plan. To cover tax obligations on this grant, 1,828 shares were withheld by the company, a non-market, tax-withholding transaction. After these entries, Silva directly holds 4,645 Cingulate common shares.